Results 91 to 100 of about 20,699 (254)

The economic impact of potentially inappropriate medications in older stroke patients: a comparison of criteria

Revista Cubana de Medicina Militar
Background: Potentially inappropriate medications (PIMs) disproportionally affect the quality of life of patients aged 65 years or older and are associated with increased direct healthcare costs.
Tho Kieu Anh Pham, Thi Bui Nhu Ngoc Ho, Rebecca Susan Dewey, Van De Tran   +3 more
doaj  

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Causality assessment tool for drug‐induced acute kidney injury in patients admitted to intensive care units: Requirements from a multicentre retrospective study in the Netherlands reusing data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to provide key requirements for a drug‐induced acute kidney injury (d‐AKI) causality assessment tool (CAT) for intensive care unit (ICU) patients, using vancomycin‐induced AKI (v‐AKI) as a test case. Methods A retrospective review was conducted by medical experts of electronic health records of ICU patients from 14 Dutch ICUs.
Joanna E. Klopotowska, Izak A. R. Yasrebi‐de Kom, Nicolette F. de Keizer, Dave A. Dongelmans, on behalf of the RESCUE Study group, Merijn C. Reuland, Irma M. Rigter, Peter F. Schutte, Ilona T. Spaan, Dorieke van Balen, Stefaan Hendriks, Petronella E. Deetman, Cedric Lau, Wytze J. Vermeijden, Marieke G. J. Schouten, Joost B. Masselink, Peter E. Spronk, Marnix Kuindersma, Hendrikus J. M. van Kan, Anne Wellink, Abraham J. Valkenburg, Andre Wieringa, Walter M. van den Bergh, Maurits H. Renes, Wouter Bult, Frouke M. Engelaer, Nienke van Rein, Martijn Hoeksema, Janneke M. van den Broek, Elsbeth Wesselink, Ilse M. Purmer, Thomas Ottens, Bertha E. Bosma, Sjoerd H. W. van Bree, Barbara Festen, Hendrick J. W. Lammers, Rob J. Bosman, Rogier M. Determann, Eric J. F. Franssen, Attila Karakus, Lenneke. E. M. Haas, Freek van Gorp, Dylan W. de Lange, Maaike A. Sikma, Esther V. Uijtendaal   +44 more
wiley   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Usability of APIMedOlder: A Web Application to Manage Potentially Inappropriate Medication in Older Adults

Acta Médica Portuguesa
Introduction: Considering the increase in the proportion of the older population worldwide, the demand for health system resources also arises. These tools optimize clinical decision-making, thus avoiding iatrogenesis and thus contributing to a better ...
Daniela A. Rodrigues, Ana I. Plácido, Ramona Mateos-Campos, Adolfo Figueiras, Maria Teresa Herdeiro, Fátima Roque   +5 more
doaj   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

The frequency of potentially inappropriate medication use according to the Beers' criteria in elderly people at the therapy departments of a multidisciplinary hospital

Терапевтический архив, 2015
Aim. To analyze the frequency of potentially inappropriate medication use according to the Beers' criteria in elderly people at the therapy departments of a hospital. Subjects and methods.
D A Sychev, K S Danilina, O V Golovina
doaj  

Patient‐reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme

British Journal of Clinical Pharmacology, EarlyView.
Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker, Lisa Cuba, Frank Dörje, Martin F. Fromm, Markus Metzler   +4 more
wiley   +1 more source

Economic evaluations of antiobesity medications: A systematic literature review

British Journal of Clinical Pharmacology, EarlyView.
The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković, Almir Fajkić, Andrea Katrin Faour, Mirna Momčilović, Petra Turčić, Andrej Belančić   +5 more
wiley   +1 more source